Research • Advancing what works in brain medicine

Research at Radial

Backed by research.
Driven by care.

Radial clinicians don't just follow the research, they conduct it. From neuromodulation to digital psychiatry, our team actively publishes and participates in clinical trials, ensuring every patient receives care that is grounded in the best available evidence.

Research areas

Movement Disorders

Schizophrenia Spectrum Disorders

Bipolar

Personality Disorders

OCD

PTSD

Anxiety

Depression

Publications

This is some text inside of a div block.

Psychedelic Therapy: A Primer for Primary Care Clinicians—N, N-Dimethyltryptamine and Ayahuasca

Kenneth Shinozuka, Burton J Tabaac, Alejandro Arenas, Bryce D Beutler, Kirsten Cherian, Viviana D Evans, Chelsey Fasano, Owen S Muir

DMT is among the least understood psychedelics entering therapeutic research — and patient questions are outpacing clinical preparation. This primer offers primary care providers a practical evidence review for informed conversations.

This is some text inside of a div block.

Psychedelic Therapy: A Primer for Primary Care Clinicians—Ibogaine

Kirsten Cherian, Kenneth Shinozuka, Burton J Tabaac, Alejandro Arenas, Bryce D Beutler, Viviana D Evans, Chelsey Fasano, Owen S Muir

Ibogaine carries both remarkable therapeutic promise and significant safety considerations. This primer helps primary care clinicians understand the evidence, risks, and clinical context for this powerful plant-derived compound.

This is some text inside of a div block.

Psychedelic Therapy: A Primer for Primary Care Clinicians—The Strengths, Weaknesses, Opportunities, and Threats of Psychedelic Therapeutics

Owen S Muir, Kenneth Shinozuka, Bryce D Beutler, Alejandro Arenas, Kirsten Cherian, Viviana D Evans, Chelsey Fasano, Burton J Tabaac

Psychedelic therapy isn't just about individual compounds — it requires a framework for evaluating the whole field. This paper maps the strengths, weaknesses, opportunities, and threats facing psychedelic therapeutics as they move toward mainstream medicine.

This is some text inside of a div block.

Evaluating passive physiological data collection during Spravato treatment

Todd M Solomon, Matus Hajduk, Martin Majernik, Jamileh Jemison, Alexander Deschamps, Jenna Scoggins, Adam Kolar, Miguel Amável Pinheiro, Peter Dubec, Ondrej Skala, Owen Muir, Amanda Tinkelman, Daniel R Karlin, Robert Barrow

Spravato sessions generate rich physiological data — but is anyone capturing it? This study evaluates passive data collection during esketamine treatment, exploring whether wearable monitoring can yield clinically meaningful insights without disrupting care.

This is some text inside of a div block.

Real world efficacy and safety of various accelerated deep TMS protocols for major depression

Yiftach Roth, Colleen A Hanlon, Gaby Pell, Samuel Zibman, Tal Harmelech, Owen S Muir, Carlene MacMillan, Tim Prestley, David C Purselle, Thomas Knightly, Aron Tendler

Not all accelerated Deep TMS protocols are created equal — so which works best? This Phase IV analysis compared multiple accelerated dosing schedules in real-world MDD patients, finding strong and comparable efficacy across 2, 3, 5, and 10 sessions per day.

This is some text inside of a div block.

Deep TMS H1 Coil treatment for depression: Results from a large post marketing data analysis

Aron Tendler, Stephan Goerigk, Samuel Zibman, Salomé Ouaknine, Tal Harmelech, Gaby S Pell, Abraham Zangen, Steven A. Harvey, Geoffrey Grammer, Jimmy Stehberg, Oluremi Adefolarin, Owen Muir, Carlene MacMillan, Diana Ghelber, Walter Duffy, Irakli Mania, Zeeshan Faruqui, Faisal Munasifi, Todd Antin, Frank Padberg, Yiftach Roth

What happens when you look at Deep TMS outcomes across more than a thousand patients in real clinical practice? This large post-marketing analysis confirms high response and remission rates for the H1 coil in community settings, with durable effects.

This is some text inside of a div block.

Remote monitoring and AI for detecting tardive dyskinesia and improving patient outcomes.

A Sterns, L Larsen, B Grimm, OS Muir

Tardive dyskinesia disrupts lives — and often goes unrecognized until it's advanced. This study examines how remote AI monitoring can detect movement abnormalities earlier, enabling timely clinical response and better long-term patient outcomes.

This is some text inside of a div block.

Remission rates following deep TMS for treatment-resistant OCD

Roman Gersner, Aron Tendler, Mehmet Kemal Arikan, Ryan Vidrine, Geoff Grammer, Owen Müir, Carlene MacMillan, Rebecca Sinclair, Saad Shakir, David Kent, Raul Rodriguez, Nicholas Evangelidis, Deborah Kim, Tal Harmelech, Yiftach Roth

Treatment-resistant OCD can leave patients cycling through failed medication trials for years. This study reports remission rates following Deep TMS for OCD, demonstrating that neuromodulation offers a meaningful path forward for patients who haven't responded to conventional care.

This is some text inside of a div block.

Long-term outcomes of a course of deep TMS for treatment-resistant OCD

Tal Harmelech, Aron Tendler, Mehmet Kemal Arikan, Hamide Laçin Çetin, Muhammed Taha Esmeray, Reyhan Ilhan, Ryan Vidrine, Owen Muir, Carlene MacMillan, Rebecca Sinclair, Saad Shakir, David Kent, Nicholas Evangelidis, Yiftach Roth

Relief from OCD matters — but so does how long it lasts. This study tracks long-term outcomes following a course of Deep TMS for treatment-resistant OCD, providing some of the most durable follow-up data available for this intervention.

This is some text inside of a div block.

Mental health clinicians’ attitudes toward narcissistic personality disorder.

Owen Muir, Jillian N Weinfeld, Danny Ruiz, Dmitry Ostrovsky, Miguel Fiolhais, Carlene MacMillan

Narcissistic personality disorder is one of psychiatry's most stigmatized diagnoses — even among the clinicians treating it. This study surfaces the attitudes and biases mental health professionals hold toward NPD, with implications for training, diagnosis, and therapeutic alliance.

This is some text inside of a div block.

Real-world efficacy of deep TMS for obsessive-compulsive disorder: Post-marketing data collected from twenty-two clinical sites

Yiftach Roth, Aron Tendler, Mehmet Kemal Arikan, Ryan Vidrine, David Kent, Owen Muir, Carlene MacMillan, Leah Casuto, Geoffrey Grammer, William Sauve, Kellie Tolin, Steven Harvey, Misty Borst, Robert Rifkin, Manish Sheth, Brandon Cornejo, Raul Rodriguez, Saad Shakir, Taylor Porter, Deborah Kim, Abraham Zangen

Deep TMS for OCD has shown promise in controlled trials — but how does it perform across dozens of real-world clinics? This post-marketing analysis of over 1,000 patients from 22 sites confirms strong efficacy for obsessive-compulsive disorder in routine clinical practice.

This is some text inside of a div block.

TMS Treatment With The H1 Coil in Youth Age 10-21 Effective In Ameliorating MDD Symptoms

Owen Muir, Danny Ruiz, Rebecca Abbott-Sinclair, Carlene MacMillan

Depression in young people aged 10 to 21 demands safe, effective options beyond medication. This study demonstrates that TMS with the H1 coil meaningfully reduces depressive symptoms in youth, supporting its clinical use in younger populations.

Learn more about our team